Wyeth Buys Thiakis Ltd.

Wyeth Pharmaceuticals, a unit of Wyeth (NYSE: WYE), has acquired Thiakis Ltd., a UK-based developer of peptide hormones for the treatment of obesity. The deal includes a $30 million up-front payment, and up to $120 million in possible earn-outs. Thiakis raised a £10 million Series A round in 2006 from Novo AS, Advent Venture Partners, The Royal Society, Esperante, Consensus Business Group, NPI Ventures and Imperial Innovations.

North AmericaUSBriefs